LIXTE Advances LB-100 PP2A Inhibitor into Clinical Trials for Ovarian and Colon Cancer
LIXTE's LB-100 is a novel PP2A inhibitor in proof-of-concept trials for ovarian clear cell carcinoma and metastatic colon cancer, aiming to boost chemotherapy and radiation efficacy while reducing side effects. The company holds comprehensive patents on activation lethality and has shown tolerable doses linked to anti-cancer activity in clinical-stage studies.
1. Clinical-Stage Focus and Portfolio
LIXTE is a clinical-stage pharmaceutical company focused on cancer drug development, pursuing new targets and data-driven solutions to improve the efficacy and safety of existing cancer treatments.
2. Lead Program LB-100 Mechanism
LB-100 is a first-in-class small-molecule PP2A inhibitor designed to improve the therapeutic index of chemotherapy and radiation by enhancing anti-cancer activity while minimizing damage to healthy tissue.
3. Patent Protection in Activation Lethality
The company holds a comprehensive patent portfolio covering activation lethality, securing exclusive rights to LB-100's novel mechanism and supporting future combination therapies with chemotherapies and immunotherapies.
4. Ongoing Proof-of-Concept Trials
Proof-of-concept trials for LB-100 are underway in ovarian clear cell carcinoma and metastatic colon cancer, with existing data showing tolerable dosing associated with anti-cancer activity and plans to expand study cohorts.